Urology
Volume 75, Issue 2 , Pages 407-413 , February 2010

Canary Prostate Active Surveillance Study: Design of a Multi-institutional Active Surveillance Cohort and Biorepository

  • Lisa F. Newcomb

      Affiliations

    • Department of Urology, University of Washington, Seattle, Washington
    • ,
  • James D. Brooks

      Affiliations

    • Department of Urology, Stanford University, Stanford, California
    • ,
  • Peter R. Carroll

      Affiliations

    • Department of Urology, University of California at San Francisco, San Francisco, California
    • ,
  • Ziding Feng

      Affiliations

    • Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Martin E. Gleave

      Affiliations

    • Prostate Centre, University of British Columbia, Vancouver, British Columbia
    • ,
  • Peter S. Nelson

      Affiliations

    • Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington
    • Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Ian M. Thompson

      Affiliations

    • Department of Urology, University of Texas Health Sciences Center, San Antonio, Texas
    • ,
  • Daniel W. Lin

      Affiliations

    • Department of Urology, University of Washington, Seattle, Washington
    • Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • Corresponding Author InformationReprint requests: Daniel W. Lin, M.D., Department of Urology, Box 356510, 1959 NE Pacific St, University of Washington, Seattle, WA 98195

Received 17 April 2009 ,Accepted 29 May 2009.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  2. Yatani R, Chigusa I, Akazaki K, et al. Geographic pathology of latent prostatic carcinoma. Int J Cancer. 1982;29:611–616
  3. Konety BR, Bird VY, Deorah S, et al. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era. J Urol. 2005;174:1785–1788discussion:1788
  4. Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008;19:175–181
  5. Collin SM, Martin RM, Metcalfe C, et al. Prostate-cancer mortality in the USA and UK in 1975–2004: an ecological study. Lancet Oncol. 2008;9:445–452
  6. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–1328
  7. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94:981–990
  8. Yao SL, Lu-Yao G. Understanding and appreciating overdiagnosis in the PSA era. J Natl Cancer Inst. 2002;94:958–960
  9. Andriole GL, Grubb RL, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310–1319
  10. Choo R, Klotz L, Danjoux C, et al. Feasibility Study (Watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression). J Urol. 2002;167:1664–1669
  11. Albertsen PC, Hanley JA, Fine J. 20-Year outcomes following conservative management of clinically localized prostate cancer. J Am Med Assoc. 2005;293:2095–2101
  12. Parker C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol. 2004;5:101–106
  13. Dong F, Kattan MW, Steyerberg EW, et al. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. J Urol. 2008;180:150–154discussion:154
  14. Kattan MW, Cuzick J, Fisher G, et al. Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer. 2008;112:69–74
  15. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliL. N Engl J Med. 2004;350:2239–2246
  16. Roehl KA, Han M, Ramos CG, et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172:910–914
  17. Dall'Era MA, Cooperberg MR, Chan JM, et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer. 2008;112:1650–1659
  18. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177:2106–2131
  19. Kattan MW, Eastham JA, Wheeler TM, et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol. 2003;170:1792–1797
  20. Steyerberg EW, Roobol MJ, Kattan MW, et al. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol. 2007;177:107–112
  21. Cooperberg MR, Broering JM, Kantoff PW, et al. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007;178:S14–S19
  22. Cooperberg MR, Lubeck DP, Meng MV, et al. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22:2141–2149
  23. van As NJ, Parker CC. Active surveillance with selective radical treatment for localized prostate cancer. Cancer J. 2007;13:289–294
  24. Dall'Era MA, Konety BR, Cowan JE, et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008;112:2664–2670
  25. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol. 2006;24:46–50
  26. Carter HB, Kettermann A, Warlick C, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol. 2007;178:2359–2365
  27. Patel MI, DeConcini DT, Lopez-Corona E, et al. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol. 2004;171:1520–1524
  28. van den Bergh RCN, Roemeling S, Roobol MJ, et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol. 2009;55:1–8
  29. Bill-Axelson A, Holmberg L, Filen F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst. 2008;100:1144–1154
  30. Wilt TJ, Brawer MK, Barry MJ, et al. The Prostate Cancer Intervention Versus Observation Trial (VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer). Contemp Clin Trials. 2009;30:81–87
  31. Donovan J, Hamdy F, Neal D, et al. Prostate testing for cancer and treatment (ProtecT) feasibility study. Health Technol Assess. 2003;7:1–88
  32. Parulekar WR, McKenzie M, Chi KN, et al. Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group. Curr Oncol. 2008;15:179–184
  33. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644–648
  34. Demichelis F, Fall K, Perner S, et al. TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26:4596–4599
  35. Narod SA, Seth A, Nam R. Fusion in the ETS gene family and prostate cancer. Br J Cancer. 2008;99:847–851
  36. Gopalan A, Leversha MA, Satagopan JM, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res. 2009;69:1400–1406
  37. Winget M, Kincaid H, Lin P, et al. A web-based system for managing and coordinating multiple multisite studies. Clin Trials. 2005;2:42–49
  38. Pepe MS. Study design and hypothesis testing. In: The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford: Oxford University Press; 2003;p. 214–252

 This work was supported by the Canary Foundation and Early Detection Research Network (EDRN) of the National Cancer Institute (NCI).

PII: S0090-4295(09)00765-1

doi: 10.1016/j.urology.2009.05.050

Urology
Volume 75, Issue 2 , Pages 407-413 , February 2010

Article Tools